DCW Limited (NSE:DCW)
India · Delayed Price · Currency is INR | Market Cap | 22.12B |
| Revenue (ttm) | 20.00B |
| Net Income (ttm) | 302.84M |
| Shares Out | 295.16M |
| EPS (ttm) | 1.03 |
| PE Ratio | 72.75 |
| Forward PE | n/a |
| Dividend | 0.10 (0.13%) |
| Ex-Dividend Date | n/a |
| Volume | 2,622,654 |
| Average Volume | 1,559,180 |
| Open | 77.00 |
| Previous Close | 76.80 |
| Day's Range | 72.88 - 80.18 |
| 52-Week Range | 63.50 - 113.00 |
| Beta | -0.36 |
| RSI | 42.94 |
| Earnings Date | Aug 11, 2025 |
About Intra-Cellular Therapies
DCW Limited engages in the manufacture and sale of heavy chemical products in India. It offers specialty chemicals, including chlorinated poly vinyl chloride, synthetic iron oxide pigment, and synthetic rutile; intermediate chemicals comprising sodium bicarbonate, hydrochloric acid, liquid chlorine, trichloroethylene, perchloroethylene, ferric chloride, sodium hypochlorite, and ammonium bicarbonate; and commodity chemicals, such as soda ash, caustic soda, and poly vinyl chloride. The company’s products are used as key ingredients for the manufa... [Read more]
Financial Performance
In 2024, DCW Limited's revenue was 20.00 billion, an increase of 6.88% compared to the previous year's 18.72 billion. Earnings were 302.84 million, an increase of 93.39%.
Financial StatementsNews
DCW to invest Rs 140 crore for expansion of CPVC production capacity
DCW Limited, a renowned speciality chemical firm in India, is investing Rs 140 crore to expand its CPVC manufacturing capacity from 20,000 to 50,000 MT. With 20,000 MT operational by Q2 FY26 and an ad...